Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 2, 2011, Pages 192-199

  Chen, D Y ^a,b,c,d   Shen, G H ^c,e   Chen, Y M ^a,b,c   Chen, H H ^a,b,c   Lin, C C ^b,c   Hsieh, C W ^a,b,c,d   Lan, J L ^a,b,c,d,f  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

IP 10; Isoniazid prophylaxis; Rheumatoid arthritis; TNF inhibitors; Tuberculosis

Indexed keywords

EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AGED; ANTIGENS, BACTERIAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; KINETICS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAIWAN; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651436421     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Carmona L, Hernandez-Garcia C, Vadillo C, et al., and the EMECAR Study Group. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 1436-1439. (Pubitemid 36835436)
2. Gomez-Reino J J, Carmona L, Valverde V R, Mola E M, Mola E M, Montero M D, on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
3. Gardam M A, Keystone E C, Menzies R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of a ction and clinical management. Lancet Infect Dis 2003; 3: 148-155.
4. Furst D E, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002; 61: 62-63.
5. Carmona L, Gomez-Reino J J, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
6. Porsa E, Cheng L, Seale M M, et al. Comparison of a new ESAT-6/CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderaterisk population. Clin Vaccine Immunol 2006; 13: 53-58.
7. Brock I, Weldingh K, Lillebaek T, Folllmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170: 65-69.
8. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1361.
9. Pratt A, Nicholl K, Kay L. Use of the QuantiFERON TB Gold test as a part of a screening programme in patients with RA under consideration for treatment with anti-TNF-α agents: the Newcastle (UK) experience. Rheumatology 2007; 46: 1036-1037.
10. Sellam J, Hamdi H, Roy C, et al. Comparison of in vitros pecific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007; 66: 1610-1615.
11. Matulis G, Juni P, Villiger P M, Gadola S D. Detection of latent tuberculosis in immunocompromised patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigenspecific IFN-γ assay. Ann Rheum Dis 2008; 67: 84-90.
12. Luetkemeyer A F, Charlebois E D, Flores L L, et al. Comparison of an interferon-gamma release assay to tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: 737-742.
13. Ferrero E, Biswas P, Vettoretto K, et al. Macrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leukocytes subpopulations: focus on gammadelta cells. Immunology 2003; 108: 365-374.
14. Azzurri A, Sow O Y, Amedei A, et al. IFN-γ-inducible protein 10 and pentraxin 3 levels are tools for monitoring infl ammation and disease activity in M. tuberculosis infection. Microbes Infect 2005; 7: 1-8.
15. Pokkali S, Das S D, Logamurthy R. Expression of CXC and CC type of chemokines and its receptors in tuberculous and non-t uberculous effusions. Cytokine 2008; 41: 307-314.
16. Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008; 32: 1607-1615.
17. Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma? PLoS ONE 2008; 3: e3901.
18. Barnes P F, Wizel B. Type 1 cytokines and the pathogenesis of tuberculosis. Am J Respir Crit Care Med 2000; 161: 1773-1774.
19. Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
20. Hsueh P R, Liu Y C, So J, Liu C Y, Yang P C, Luh K T. Mycobacterium tuberculosis in Taiwan. J Infect 2006; 52: 77-85.
21. Prevoo M L L, van't Hof M A, Kuper H H, van Leeuwen M A, van de Putte L B A, van Riel P L C M. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
22. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-1395.
23. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-?-based assay using new antigens. Am J Respir Crit Care Med 2004; 170: 59-64.
24. Ruhwald M, Bjerregaard-Andersen M, Rabna P, et al. IP-10/ CXCL10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes Infect 2007; 9: 806-812.
25. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
26. Ding L W, Lai C C, Lee L N, Hsueh P R. Disease caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 1997-2003. Epidemiol Infect 2006; 134: 1060-1067.
27. Kunimoto D, Der E, Beckon A, et al. Use of the QuantiFERONTB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic. Int J Tuberc Lung Dis 2009; 13: 726-730.
28. Casas I, Latorre I, Esteve M, et al. Evaluation of interferongamma release assays in the diagnosis of recent tuberculosis infection in health care workers. PloS ONE 2009; 4: e6686.
29. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009; 33: 586-593.
30. Lighter J, Rigaud M, Huie M, Peng C H , Pollack H. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int J Tuberc Lung Dis 2009; 13: 731-736.
31. Ruhwald M, Petersen J, Kofoed K, et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PloS ONE 2008; 3: e2858.
32. Petrucci R, Amer N A, Gurgel R Q, et al. Interferon gamma, interferon-gamma-induced-protein 10, and tuberculin responses of children at high risk of tuberculosis infection. Pediatr Infect Dis J 2008; 27: 1073-1077.
33. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328-1334.
34. Lee J Y, Choi H J, Park I N, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28: 24-30.
35. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-1132.